Mouton JW, Hollander JG: Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994, 38: 931-936.
Article
PubMed Central
CAS
PubMed
Google Scholar
Craig WA: Does the dose matter? Clin Infect Dis 2001, 33 Suppl 3: S233-S237. 10.1086/321854
Article
CAS
PubMed
Google Scholar
Craig WA, Ebert SC: Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother 1992, 36: 2577-2583.
Article
PubMed Central
CAS
PubMed
Google Scholar
Mouton JW, Vinks AA: Is continuous infusion of β-lactam antibiotics worthwile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996, 38: 5-15.
Article
CAS
PubMed
Google Scholar
Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V, Chaowagul W, White NJ: Pharmacokinetic-pharmacodynamic evaluation of cefatzidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000, 50: 184-191. 10.1046/j.1365-2125.2000.00179.x
Article
PubMed Central
CAS
PubMed
Google Scholar
Boselli E, Breilh D, Rimmele T, Poupelin JC, Saux MC, Chassard D, Allaouchiche B: Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004, 30: 989-991. 10.1007/s00134-004-2171-2
Article
PubMed
Google Scholar
Buijk SLCE, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA: Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002, 49: 121-128. 10.1093/jac/49.1.121
Article
CAS
PubMed
Google Scholar
Dalle JH, Gnansounou M, Husson MO, Lambilliotte A, Mazingue F, Nelken B: Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer. J Pediatr Hematol Oncol 2002, 24: 714-716. 10.1097/00043426-200212000-00006
Article
PubMed
Google Scholar
Egerer G, Goldschmidt H, Hensel M, Harter C, Schneeweiss A, Ehrhard I, Bastert G, Ho AD: Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation. Bone Marrow Transplant 2002, 30: 427-431. 10.1038/sj.bmt.1703660
Article
CAS
PubMed
Google Scholar
Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA: Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000, 179: 436-440. 10.1016/S0002-9610(00)00388-3
Article
CAS
PubMed
Google Scholar
Nicolau DP, McNabb JC, Lacy MK, Quintiliani R, Nightingale CH: Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001, 17: 497-504. 10.1016/S0924-8579(01)00329-6
Article
CAS
PubMed
Google Scholar
Vinks AATMM, Touw DJ, Heijerman HGM, Danhof M, de Leede GPJ, Bakker W: Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit 1994, 16: 341-348.
Article
CAS
PubMed
Google Scholar
Harding SM, Ayrton J, Thornton JE, Munro AJ, Hogg MIJ: Pharmacokinetics of ceftazidime in normal subjects. J Antimicrob Chemother 1981, 261.
Google Scholar
Leroy A, Leguy F, Borsa F, Spencer GR, Fillastre JP, Humbert G: Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob Agents Chemother 1984, 25: 638-642.
Article
PubMed Central
CAS
PubMed
Google Scholar
Van Dalen R, Vree TB, Baars AM, Termond E: Dosage adjustment for ceftazidime in patients with impaired renal function. Eur J Clin Pharmacol 1986, 30: 597-605. 10.1007/BF00542421
Article
CAS
PubMed
Google Scholar
Walstad RA, Dahl K, Hellum KB, Thurmann-Nielsen E: The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent furosemide therapy. Eur J Clin Pharmacol 1988, 35: 273-279. 10.1007/BF00558265
Article
CAS
PubMed
Google Scholar
Joos B, Schmidli M, Keusch G: Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. Nephrol Dial Transplant 1996, 11: 1582-1585.
Article
CAS
PubMed
Google Scholar
Matzke GR, Frye F, Joy MS, Palevsky PM: Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother 2000, 44: 1639-1644. 10.1128/AAC.44.6.1639-1644.2000
Article
PubMed Central
CAS
PubMed
Google Scholar
Nikolaidis P, Tourkantonis A: Effect of hemodialysis on ceftazidime pharmacokinetics. Clin Nephrol 1985, 24: 142-146.
CAS
PubMed
Google Scholar
Vincent HH, Vos MC, Akcahuseyin E, Goessens WHF, van Duyl WA, Schalekamp MADH: Drug clearance by continuous haemodiafiltration. Blood Purif 1993, 11: 99-107.
Article
CAS
PubMed
Google Scholar
Traunmüller F, Schenk P, Mittermeyer C, Thalhammer-Scherrer R, Ratheiser K, Thalhammer F: Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother 2002, 49: 129-134. 10.1093/jac/49.1.129
Article
PubMed
Google Scholar
Sato T, Okamoto K, Kitaura M, Kukita I, Kikuta K, Hamaguchi M: The pharmacokinetics of ceftazidime during hemodiafiltration in critically ill patients. Artif Organs 1999, 23: 143-145. 10.1046/j.1525-1594.1999.06218.x
Article
CAS
PubMed
Google Scholar
Keller F, Bohler J, Czok D, Zellner D, Mertz AKH: Individualized drug dosage in patients treated with continuous hemofiltration. Kidney Int 1999, 72: S29-S31.
Article
CAS
Google Scholar
Castela N, Taburet AM, Carlet J, Nitenberg G, Wolf M, Sollet JP: Pharmacokinetics of ceftazidime during continuous infusion in intensive care patients [abstract 11]. In Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1994:16.
Google Scholar
Jehl F, Gallion C, Monteil H: High-performance liquid chromatography of antibiotics. J Chromatogr 1990, 531: 509-548.
Article
CAS
PubMed
Google Scholar
Bohler J, Donauer J, Keller F: Pharmacokinetics principles during continuous renal replacement therapy: drugs and dosage. Kidney Int 1999, 24-28.
Google Scholar
Benko AS, Cappelletty DM, Kruse JA, Rybak MJ: Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996, 40: 691-705.
PubMed Central
CAS
PubMed
Google Scholar
Van Dalen R, Vree TB: Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 1990, 16 Suppl 3: S235-S238. 10.1007/BF01709707
Article
CAS
PubMed
Google Scholar
Farina A, Porra R, Cotichini V, Doldo A: Stability of reconstituted solutions of ceftazidime for injections: an HPLC and CE approach. J Pharm Biomed Anal 1999, 20: 521-530. 10.1016/S0731-7085(99)00057-6
Article
CAS
PubMed
Google Scholar
Isla A, Arzuaga A, Maynar J, Gascon AR, Solinis MA, Corral E, Pedraz JL: Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC. J Pharm Biomed Anal 2005, 39: 996-1005. 10.1016/j.jpba.2005.05.027
Article
CAS
PubMed
Google Scholar
Malone RS, Fish DN, Abraham E, Teitelbaum I: Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001, 45: 3148-3155. 10.1128/AAC.45.11.3148-3155.2001
Article
PubMed Central
CAS
PubMed
Google Scholar
Isla A, Gascon AR, Maynar J, Arzuaga A, Toral D, Pedraz JL: Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin Ther 2005, 27: 599-608. 10.1016/j.clinthera.2005.05.004
Article
CAS
PubMed
Google Scholar